Nab-paclitaxel in combination with weekly carboplatin with concurrent radiotherapy in stage III non-small cell lung cancer

Oncologist

Volumn 20, Issue 5, 2015, Pages 491-492

  Lammers, Philip Edward ^a   Lu, Bo ^b   Horn, Leora ^c   Shyr, Yu ^c   Keedy, Vicki ^c  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; TREATMENT OUTCOME; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL;

EID: 84929088300     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0030     Document Type: Article

References (0)